Abstract
Purpose
To identify risk factors for chemotherapy-related nausea.
Methods
We examined risk factors for nausea in 1,696 patients from three multicenter studies conducted from 1998 to 2004. All patients were beginning a chemotherapy regimen containing cisplatin, carboplatin, or doxorubicin. Nausea was assessed on a 1–7 scale four times a day for 4 days by diary.
Results
First, average nausea for breast cancer patients receiving doxorubicin (mean = 2.31) was significantly greater than for other patients receiving doxorubicin (mean = 1.82), patients receiving cisplatin (mean = 1.88), and patients receiving carboplatin (mean = 1.45), Ps < 0.01. Second, mean nausea decreased steadily with age, P < 0.0001. Third, patients rating themselves more susceptible to nausea had significantly more nausea (adjusted mean = 2.51) than patients rating themselves less susceptible (adjusted mean = 1.92) and were 2.8 times more likely to experience severe nausea, Ps < 0.0001. Fourth, expected nausea was a significant predictor of average nausea, P = 0.034, but not severe nausea, P = 0.31. Last, no evidence that gender is a significant predictor of nausea in 299 patients with gender neutral cancers, P = 0.35.
Conclusions
Specific patient characteristics, especially younger age and perceived susceptibility to nausea, can help clinicians in the early identification of patients who are more susceptible to treatment-related nausea.
Similar content being viewed by others
References
Klastersky J, Schimpff SC, Senn HJ (1999) Supportive care in cancer, 2nd edn. Marcel Deckker, New York
Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. Support Care Cancer 5:307–313
Morrow GR, Roscoe JA, Hickok JT (1998) Nausea and vomiting. In: Holland JC (ed) Psycho-oncology. Oxford University Press, New York, pp 476–484
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880–2886
(1999) ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 56:729–764
Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? The Journal of Supportive Oncology 2:1–10
Hesketh PJ, Grunberg SM, Herrstedt J, de WR, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360
Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150
Herrstedt J, Dombernowsky P (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic & Clinical Pharmacology & Toxicology 101:143–150
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994
Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelson DP, Braun DW, Bordin LA, Braun TJ (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909
(2008): National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: antiemesis, V.2.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed February 3, 2009
Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772
Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:116–123
Montgomery GH (2000) Pre-infusion expectations predict post-treatment nausea during repeated adjuvant chemotherapy infusions for breast cancer. Br J Health Psychol 5:105–119
Rhodes VA, Watson PM, McDaniel RW, Hanson BM, Johnson MH (1995) Expectation and occurrence of postchemotherapy side effects: nausea and vomiting. Cancer Pract 3:247–253
Roscoe JA, Hickok JT, Morrow GR (2000) Patient expectations as predictor of chemotherapy-induced nausea. Annals Behav Med 22:121–126
Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, Banerjee TK (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 101:2701–2708
Olver IN, Taylor AE, Whitford HS (2005) Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences. Psychooncology 14:25–33
Roscoe JA, Jean-Pierre P, Shelke AR, Kaufman ME, Bole C, Morrow GR (2006) The role of patients' response expectancies in side effect development and control. Curr Probl Cancer 30:40–98
Colagiuri B, Roscoe JA, Morrow GR, Atkins JN, Giguere JK, Colman LK (2008) How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 113:654–661
Shelke AR, Roscoe JA, Morrow GR, Colman LK, Banerjee TK, Kirshner JJ (2008) Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study. J Pain Symptom Manage 35:381–387
Roscoe JA, Morrow GR, Hickok JT, Bushunow PW, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr, Atkins JN (2003) The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting: a URCC CCOP multicenter study. J Pain Symptom Manage 26:731–742
Burish TG, Carey MP, Krozely MG, Greco FA (1987) Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol 55:42–48
Carey MP, Burish TG (1988) Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol Bull 104:307–325
(2004) Chemotherapy-induced nausea and vomiting (CINV): prevention, detection, and treatment—how are we doing? ONS News 19:61–62
Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. The Journal of Supportive Oncology 5:5–12
Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622–627
Blakeslee S (2005) Techniques to manage the mind—how hypnosis is gaining respect. Magazine for Hypnosis and Hypnotherapy at http://hypnos.co.uk/hypnomag/hypnosisnews/hypnosisrespect.htm. Accessed February 3, 2009
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by grant number 1R25-CA102618-01A1 from the National Cancer Institute.
Rights and permissions
About this article
Cite this article
Roscoe, J.A., Morrow, G.R., Colagiuri, B. et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18, 869–876 (2010). https://doi.org/10.1007/s00520-009-0723-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-009-0723-2